N/A
Completed N=322
Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)
Source: ClinicalTrials.gov NCT03775213 ↗Enrolled (actual)
322
Serious AEs
—
Results posted
Jan 2023
Primary outcomePrimary: Number of Participants Who Chose Active Monitoring (AM). — 28; 18 Participants
Summary
The purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (DCIS).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Chose Active Monitoring (AM). |
28; 18 | — |
| SECONDARY Number of Participants Who Found the Treatment Option Acceptable. |
32; 32; 50; 47; 34; 38 | — |
| SECONDARY Number of Participants Who Perceived Active Monitoring as Risky. |
18; 17 | — |
| SECONDARY Number of Participants Who Chose Mastectomy. |
14; 15 | — |
| SECONDARY Change in Self-perceived Knowledge About DCIS. |
2; 2.5 | — |
Eligibility Criteria
Inclusion Criteria
- Sex: Female
- Age: 50-79 years
- Has had a negative mammographic screen in the past 12 months
Exclusion Criteria
- Personal history of breast cancer
Data sourced from ClinicalTrials.gov (NCT03775213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.